Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Products under Development by Stage of Development | 7 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Products under Development by Therapy Area | 8 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Products under Development by Indication | 9 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Products under Development by Companies | 12 | 2 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Products under Development by Universities/Institutes | 14 | 2 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 2 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Companies Involved in Therapeutics Development | 21 | 3 |
| Galapagos NV | 21 | 1 |
| Ono Pharmaceutical Co., Ltd. | 22 | 1 |
| Ribomic Inc. | 23 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Drug Profiles | 24 | 9 |
| GLPG-1690 Drug Profile | 24 | 2 |
| ONO-8430506 Drug Profile | 26 | 1 |
| PAT-048 Drug Profile | 27 | 1 |
| RBM-006 Drug Profile | 28 | 1 |
| Small Molecule to Inhibit Autotaxin for Lung Cancer Drug Profile | 29 | 1 |
| Small Molecules to Inhibit Autotaxin for Lung Cancer and Idiopathic Pulmonary Fibrosis Drug Profile | 30 | 1 |
| Small Molecules to Inhibit Autotaxin for Oncology Drug Profile | 31 | 1 |
| X-165 Drug Profile | 32 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Dormant Projects | 33 | 1 |
| Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) Featured News &Press Releases | 34 | 3 |
| Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients | 34 | 1 |
| Sep 22, 2015: Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS | 34 | 1 |
| Feb 16, 2015: Galapagos reports positive Phase 1 results for GLPG1690 | 35 | 1 |
| Jul 01, 2014: Galapagos initiates Phase 1 study with GLPG1690, triggering EU6.6 M milestone in the alliance with Janssen Pharmaceutica | 35 | 2 |
| Appendix | 37 | 2 |
| Methodology | 37 | 1 |
| Coverage | 37 | 1 |
| Secondary Research | 37 | 1 |
| Primary Research | 37 | 1 |
| Expert Panel Validation | 37 | 1 |
| Contact Us | 37 | 1 |
| Disclaimer | 38 | 1 |